Your browser doesn't support javascript.
loading
Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy.
Chen, Manling; Liu, Xiaoyu; Peng, Nan; Zhang, Ting; Mou, Junli; He, Huizhen; Wang, Ying; Xu, Yingxi; Xing, Haiyan; Tang, Kejing; Tian, Zheng; Rao, Qing; Gu, Runxia; Qiu, Shaowei; Wang, Min; Wang, Jianxiang.
Affiliation
  • Chen M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • Liu X; Tianjin Institutes of Health Science, Tianjin, 300020, China.
  • Peng N; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • Zhang T; Tianjin Institutes of Health Science, Tianjin, 300020, China.
  • Mou J; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • He H; Tianjin Institutes of Health Science, Tianjin, 300020, China.
  • Wang Y; National Clinical Research Center for Hematologic Disease, Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China.
  • Xu Y; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • Xing H; Tianjin Institutes of Health Science, Tianjin, 300020, China.
  • Tang K; Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Tian Z; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • Rao Q; Tianjin Institutes of Health Science, Tianjin, 300020, China.
  • Gu R; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • Qiu S; Tianjin Institutes of Health Science, Tianjin, 300020, China.
  • Wang M; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Pekin
  • Wang J; Tianjin Institutes of Health Science, Tianjin, 300020, China.
Exp Hematol Oncol ; 12(1): 64, 2023 Jul 24.
Article de En | MEDLINE | ID: mdl-37488603
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Exp Hematol Oncol Année: 2023 Type de document: Article Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Exp Hematol Oncol Année: 2023 Type de document: Article Pays de publication: Royaume-Uni